A股異動︱隴神戎發2連板 習近平對中醫藥工作作出重要指示
格隆匯10月28日丨隴神戎發(300534.SZ)2連板,報7元,成交2.5億元,總市值21.2億元。

中共中央總書記、國家主席、中央軍委主席習近平近日對中醫藥工作作出重要指示指出,中醫藥學包含着中華民族幾千年的健康養生理念及其實踐經驗,是中華文明的一個瑰寶,凝聚着中國人民和中華民族的博大智慧。新中國成立以來,我國中醫藥事業取得顯著成就,為增進人民健康作出了重要貢獻。
隴神戎發的主營業務為中成藥的生產和銷售,共有滴丸劑、片劑、硬膠囊劑、膜劑等4種劑型,主要產品元胡止痛滴丸、酸棗仁油滴丸、鞣酸小檗鹼膜和七味温陽膠囊均為獨家品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.